Segment Reporting - Summary of Disaggregated Amounts that Comprise Research and Development and General and Administrative Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||
| Research and development: | ||||||
| Clinical development | $ 13,083 | $ 3,051 | $ 17,917 | $ 4,296 | ||
| Employee-related | 5,829 | 2,957 | 9,947 | 5,109 | ||
| Facility and equipment costs | 377 | 490 | 724 | 868 | ||
| Pre-clinical research | 25 | 127 | 51 | 244 | ||
| Other research and development segment expenses | 487 | 366 | 1,002 | 490 | ||
| Total research and development | 19,801 | 6,991 | 29,641 | 11,007 | ||
| General and administrative: | ||||||
| Employee-related | 2,689 | 1,945 | 5,055 | 3,661 | ||
| Professional and consulting fees | 1,198 | 1,436 | 3,247 | 3,238 | ||
| Commercial readiness | 2,405 | 343 | 3,743 | 475 | ||
| Other general and administrative segment expenses | [1] | 653 | 462 | 1,344 | 926 | |
| Total general and administrative | 6,945 | 4,186 | 13,389 | 8,300 | ||
| Total operating expenses | 26,746 | 11,177 | 43,030 | 19,307 | ||
| Loss from operations | (26,746) | (11,177) | (43,030) | (19,307) | ||
| Grant income | 22 | 44 | ||||
| Interest income | 1,672 | 926 | 2,994 | 1,860 | ||
| Interest expense | (1,575) | (236) | (3,139) | (542) | ||
| Change in fair value of warrant liabilities | (12,278) | 5,691 | (4,635) | 20,572 | ||
| Net income (loss) and comprehensive income (loss) | $ (38,905) | $ (4,796) | $ (47,766) | $ 2,583 | ||
| ||||||
| X | ||||||||||
- Definition Commercial readiness. No definition available.
|
| X | ||||||||||
- Definition Employee related research and development. No definition available.
|
| X | ||||||||||
- Definition Facility and equipment costs. No definition available.
|
| X | ||||||||||
- Definition Pre-clinical research No definition available.
|
| X | ||||||||||
- Definition Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business). No definition available.
|
| X | ||||||||||
- Definition Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate amount of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|